ArticleEuropean journal of medical research2025
The potential role of BCL2A1⁺ tissue-resident macrophages in the prognosis of Wilms tumor.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tumor-associated macrophages (TAMs) have a significant impact on the prognosis and treatment outcomes of Wilms tumor (WT) patients. To explore the key mechanisms underlying WT progression and immune therapy, this study used CIBERSORT to analyze the immune cell infiltration of 120 WT patients. Combined with single-cell RNA sequencing (scRNA-seq) data, the heterogeneity of macrophages in WT and adjacent tissues was revealed, identifying a subpopulation of tissue-resident macrophages with specific expression of BCL2A1. Further validation through immunohistochemistry (IHC) and immunofluorescence (IF) experiments confirmed the presence of BCL2A1⁺tissue-resident macrophages and elevated BCL2A1 expression is associated with advanced tumors and poor prognosis. Functional enrichment analysis suggests that BCL2A1⁺tissue-resident macrophages may promote WT progression through immune regulation and apoptosis pathways. This study is the first to identify the presence of a BCL2A1⁺tissue-resident macrophage subset in WT and reveal its critical role in tumor progression, potentially providing a novel target for personalized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.